| Tbio | E3 ubiquitin-protein ligase PDZRN3 |
E3 ubiquitin-protein ligase. Plays an important role in regulating the surface level of MUSK on myotubes. Mediates the ubiquitination of MUSK, promoting its endocytosis and lysosomal degradation. Might contribute to terminal myogenic differentiation.
This gene encodes a member of the LNX (Ligand of Numb Protein-X) family of RING-type ubiquitin E3 ligases. This protein may function in vascular morphogenesis and the differentiation of adipocytes, osteoblasts and myoblasts. This protein may be targeted for degradation by the human papilloma virus E6 protein. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]
This gene encodes a member of the LNX (Ligand of Numb Protein-X) family of RING-type ubiquitin E3 ligases. This protein may function in vascular morphogenesis and the differentiation of adipocytes, osteoblasts and myoblasts. This protein may be targeted for degradation by the human papilloma virus E6 protein. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Liver Cirrhosis, Experimental | 769 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| breast carcinoma | 1638 | 8.6e-21 |
| malignant mesothelioma | 3232 | 8.4e-08 |
| lung adenocarcinoma | 2716 | 2.6e-07 |
| psoriasis | 6694 | 6.1e-05 |
| ovarian cancer | 8520 | 6.6e-05 |
| lung cancer | 4740 | 1.8e-04 |
| Atopic dermatitis | 952 | 4.0e-04 |
| pituitary cancer | 1972 | 4.1e-04 |
| intraductal papillary-mucinous adenoma (IPMA) | 2955 | 4.5e-04 |
| invasive ductal carcinoma | 2951 | 4.7e-04 |
| Breast cancer | 3578 | 4.8e-04 |
| adrenocortical carcinoma | 1428 | 5.3e-04 |
| medulloblastoma, large-cell | 6241 | 1.4e-03 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 1.9e-03 |
| ductal carcinoma in situ | 1745 | 2.7e-03 |
| acute quadriplegic myopathy | 1158 | 4.3e-03 |
| active Crohn's disease | 922 | 6.0e-03 |
| aldosterone-producing adenoma | 665 | 1.8e-02 |
| head and neck cancer | 271 | 1.9e-02 |
| colon cancer | 1478 | 3.5e-02 |
| group 3 medulloblastoma | 4104 | 4.3e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Carcinoma | 11493 | 0.0 | 1.3 |
| Immune system cancer | 140 | 0.0 | 0.6 |
| Kidney cancer | 2613 | 0.0 | 0.6 |
| Liver cancer | 604 | 0.0 | 0.7 |
| Lymphoid leukemia | 160 | 0.0 | 0.5 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Chronic obstructive pulmonary disease | 184 | 0.0 | 1.2 |
| Heart conduction disease | 83 | 0.0 | 1.1 |
| Kidney disease | 430 | 0.0 | 1.9 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Perivascular epithelioid cell tumor | 4 | 3.172 | 1.6 |
| Disease | log2 FC | p |
|---|---|---|
| active Crohn's disease | 1.143 | 6.0e-03 |
| acute quadriplegic myopathy | -1.253 | 4.3e-03 |
| adrenocortical carcinoma | -2.914 | 5.3e-04 |
| aldosterone-producing adenoma | -1.355 | 1.8e-02 |
| Atopic dermatitis | -1.300 | 4.0e-04 |
| Breast cancer | -1.400 | 4.8e-04 |
| breast carcinoma | -1.200 | 8.6e-21 |
| colon cancer | -1.200 | 3.5e-02 |
| ductal carcinoma in situ | -1.500 | 2.7e-03 |
| group 3 medulloblastoma | -1.800 | 4.3e-02 |
| head and neck cancer | -1.600 | 1.9e-02 |
| intraductal papillary-mucinous adenoma (... | -2.400 | 4.5e-04 |
| intraductal papillary-mucinous neoplasm ... | -2.700 | 1.9e-03 |
| invasive ductal carcinoma | -3.200 | 4.7e-04 |
| lung adenocarcinoma | -1.100 | 2.6e-07 |
| lung cancer | -2.300 | 1.8e-04 |
| malignant mesothelioma | -3.700 | 8.4e-08 |
| medulloblastoma, large-cell | -3.400 | 1.4e-03 |
| ovarian cancer | -2.500 | 6.6e-05 |
| pituitary cancer | -1.700 | 4.1e-04 |
| psoriasis | -1.300 | 6.1e-05 |
MGFELDRFDGDVDPDLKCALCHKVLEDPLTTPCGHVFCAGCVLPWVVQEGSCPARCRGRLSAKELNHVLP 1 - 70 LKRLILKLDIKCAYATRGCGRVVKLQQLPEHLERCDFAPARCRHAGCGQVLLRRDVEAHMRDACDARPVG 71 - 140 RCQEGCGLPLTHGEQRAGGHCCARALRAHNGALQARLGALHKALKKEALRAGKREKSLVAQLAAAQLELQ 141 - 210 MTALRYQKKFTEYSARLDSLSRCVAAPPGGKGEETKSLTLVLHRDSGSLGFNIIGGRPSVDNHDGSSSEG 211 - 280 IFVSKIVDSGPAAKEGGLQIHDRIIEVNGRDLSRATHDQAVEAFKTAKEPIVVQVLRRTPRTKMFTPPSE 281 - 350 SQLVDTGTQTDITFEHIMALTKMSSPSPPVLDPYLLPEEHPSAHEYYDPNDYIGDIHQEMDREELELEEV 351 - 420 DLYRMNSQDKLGLTVCYRTDDEDDIGIYISEIDPNSIAAKDGRIREGDRIIQINGIEVQNREEAVALLTS 421 - 490 EENKNFSLLIARPELQLDEGWMDDDRNDFLDDLHMDMLEEQHHQAMQFTASVLQQKKHDEDGGTTDTATI 491 - 560 LSNQHEKDSGVGRTDESTRNDESSEQENNGDDATASSNPLAGQRKLTCSQDTLGSGDLPFSNESFISADC 561 - 630 TDADYLGIPVDECERFRELLELKCQVKSATPYGLYYPSGPLDAGKSDPESVDKELELLNEELRSIELECL 631 - 700 SIVRAHKMQQLKEQYRESWMLHNSGFRNYNTSIDVRRHELSDITELPEKSDKDSSSAYNTGESCRSTPLT 701 - 770 LEISPDNSLRRAAEGISCPSSEGAVGTTEAYGPASKNLLSITEDPEVGTPTYSPSLKELDPNQPLESKER 771 - 840 RASDGSRSPTPSQKLGSAYLPSYHHSPYKHAHIPAHAQHYQSYMQLIQQKSAVEYAQSQMSLVSMCKDLS 841 - 910 SPTPSEPRMEWKVKIRSDGTRYITKRPVRDRLLRERALKIREERSGMTTDDDAVSEMKMGRYWSKEERKQ 911 - 980 HLVKAKEQRRRREFMMQSRLDCLKEQQAADDRKEMNILELSHKKMMKKRNKKIFDNWMTIQELLTHGTKS 981 - 1050 PDGTRVYNSFLSVTTV 1051 - 1066 //
